Injectable Bacitracin’s Lone Indication Should Be Revoked, US FDA Panel Says

 
• By Sue Sutter

Although advisory committee members call for new studies to support the antibiotic’s extensive off-label use in surgical irrigation, they point to financial and practical hurdles to obtaining such data.

FDA Advisory Committee Feature image
An advisory committee said the benefit/risk profile for bacitracin injection's use in pediatric pneumonia is not positive.

More from US FDA Performance Tracker

More from Regulatory Trackers